Ceribell (CBLL) Cash from Investing Activities (2023 - 2026)
Ceribell (CBLL) posted Cash from Investing Activities of $22.4 million for Q1 2026, down 14.05% on a QoQ basis from $26.1 million in Q4 2025, and up 175.79% year-over-year from $8.1 million in Q1 2025.
Ceribell (CBLL) Cash from Investing Activities (2023 - 2026) Analysis & Trends
Ceribell's Cash from Investing Activities history runs 4 years deep, the most recent figure standing at $22.4 million for Q1 2026.
- Quarterly Cash from Investing Activities rose 175.79% year-over-year to $22.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$66.1 million (down 112.67% YoY) and the FY2025 annual result came in at -$118.1 million, down 7292.8% from the prior year.
- Cash from Investing Activities was $22.4 million for Q1 2026 at Ceribell, down from $26.1 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $26.1 million in Q4 2025 and bottomed at -$107.7 million in Q2 2025.
- A 4-year average of -$9.8 million and a median of -$588000.0 in 2023 frame the typical range for Cash from Investing Activities.
- Peak annual rise in Cash from Investing Activities reached 5395.74% in 2025, while the deepest fall reached 22331.06% in 2025.
- Ceribell's Cash from Investing Activities stood at -$683000.0 in 2023, then advanced by 27.82% to -$493000.0 in 2024, then soared by 5395.74% to $26.1 million in 2025, then slipped by 14.05% to $22.4 million in 2026.
- Business Quant data shows CBLL's Cash from Investing Activities at $22.4 million in Q1 2026, $26.1 million in Q4 2025, and -$6.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.85 Bn | 176.55 Bn | 6.27 Bn | -20.32 Bn |
| 2 | Stryker | 128.90 Bn | 126.02 Bn | 3.81 Bn | -185.00 Mn |
| 3 | Medtronic | 108.55 Bn | 99.33 Bn | 6.41 Bn | -917.00 Mn |
| 4 | Boston Scientific | 68.56 Bn | 67.10 Bn | 3.61 Bn | -591.00 Mn |
| 5 | Edwards Lifesciences | 48.24 Bn | 44.57 Bn | 1.29 Bn | -92.80 Mn |
| 6 | Dexcom | 28.40 Bn | 27.28 Bn | 750.30 Mn | -298.50 Mn |
| 7 | GE HealthCare Technologies | 28.15 Bn | 25.87 Bn | 1.98 Bn | -2.50 Bn |
| 8 | Smith & Nephew | 26.89 Bn | 26.31 Bn | - | - |
| 9 | Koninklijke Philips | 24.75 Bn | 21.63 Bn | 2.07 Bn | -475.32 Mn |
| 10 | Ceribell | 671.91 Mn | 530.73 Mn | 23.12 Mn | 22.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 22.44 Mn |
| Mar 31, 2026 | 22.44 Mn |
| Dec 31, 2025 | 26.11 Mn |
| Dec 31, 2025 | 26.11 Mn |
| Sep 30, 2025 | -6.94 Mn |
| Sep 30, 2025 | -6.94 Mn |
| Jun 30, 2025 | -107.69 Mn |
| Jun 30, 2025 | -107.69 Mn |
| Mar 31, 2025 | -29.61 Mn |
| Mar 31, 2025 | -29.61 Mn |
| Dec 31, 2024 | -493,000.00 |
| Dec 31, 2024 | -493,000.00 |
| Sep 30, 2024 | 183,000.00 |
| Sep 30, 2024 | 183,000.00 |
| Jun 30, 2024 | -1.16 Mn |
| Jun 30, 2024 | -1.16 Mn |
| Mar 31, 2024 | -132,000.00 |
| Mar 31, 2024 | -132,000.00 |
| Dec 31, 2023 | -683,000.00 |
| Dec 31, 2023 | -683,000.00 |